CARM vs. BLUE, KZR, FGEN, MRNS, INKT, ALLK, SCLX, CALC, GRCE, and SRZN
Should you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include bluebird bio (BLUE), Kezar Life Sciences (KZR), FibroGen (FGEN), Marinus Pharmaceuticals (MRNS), MiNK Therapeutics (INKT), Allakos (ALLK), Scilex (SCLX), CalciMedica (CALC), Grace Therapeutics (GRCE), and Surrozen (SRZN). These companies are all part of the "pharmaceutical products" industry.
Carisma Therapeutics vs.
bluebird bio (NASDAQ:BLUE) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.
87.4% of bluebird bio shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 1.4% of bluebird bio shares are held by company insiders. Comparatively, 12.6% of Carisma Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Carisma Therapeutics has lower revenue, but higher earnings than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.
bluebird bio presently has a consensus target price of $44.60, suggesting a potential upside of 793.79%. Carisma Therapeutics has a consensus target price of $1.93, suggesting a potential upside of 944.49%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than bluebird bio.
bluebird bio has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500.
In the previous week, bluebird bio had 2 more articles in the media than Carisma Therapeutics. MarketBeat recorded 2 mentions for bluebird bio and 0 mentions for Carisma Therapeutics. bluebird bio's average media sentiment score of 0.16 beat Carisma Therapeutics' score of 0.00 indicating that bluebird bio is being referred to more favorably in the media.
Carisma Therapeutics has a net margin of -314.78% compared to bluebird bio's net margin of -565.74%. bluebird bio's return on equity of -322.46% beat Carisma Therapeutics' return on equity.
bluebird bio received 1023 more outperform votes than Carisma Therapeutics when rated by MarketBeat users. However, 78.26% of users gave Carisma Therapeutics an outperform vote while only 70.34% of users gave bluebird bio an outperform vote.
Summary
Carisma Therapeutics beats bluebird bio on 10 of the 19 factors compared between the two stocks.
Get Carisma Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Carisma Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CARM) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy CARM Stock Free CARM Stock Alerts